Europe Biosimilars Market Size & Outlook, 2020-2027
Europe biosimilars market, 2016-2027 (US$M)
Related Markets
Europe biosimilars market highlights
- The Europe biosimilars market generated a revenue of USD 4,500.0 million in 2020.
- The market is expected to grow at a CAGR of 13.7% from 2021 to 2027.
- In terms of segment, recombinant non-glycosylated proteins was the largest revenue generating product in 2020.
- Recombinant Glycosylated Proteins is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2021 to 2027.
Europe data book summary
| Market revenue in 2020 | USD 4,500.0 million |
| Market revenue in 2027 | USD 11,080.0 million |
| Growth rate | 13.7% (CAGR from 2020 to 2027) |
| Largest segment | Recombinant non-glycosylated proteins |
| Fastest growing segment | Recombinant Glycosylated Proteins |
| Historical data covered | 2016 - 2019 |
| Base year for estimation | 2020 |
| Forecast period covered | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins |
| Key market players worldwide | Amgen Inc, Roche, Sandoz Group AG ADR, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Bioepis, Biocon, Viatris Inc, Celltrion Healthcare, AbbVie Inc |
Other key industry trends
- In terms of revenue, Europe region accounted for 34.0% of the global biosimilars market in 2020.
- Globally, North America is projected to lead the regional market in terms of revenue in 2027.
- North America is the fastest growing regional market and is projected to reach USD 17,204.5 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biosimilars Market Scope
Biosimilars Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe biosimilars market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimilars market will help companies and investors design strategic landscapes.
Recombinant non-glycosylated proteins was the largest segment with a revenue share of 53.94% in 2020. Horizon Databook has segmented the Europe biosimilars market based on recombinant non-glycosylated proteins, recombinant glycosylated proteins covering the revenue growth of each sub-segment from 2016 to 2027.
Europe has held the largest market share in terms of revenue due to presence of well-defined regulatory framework for biosimilars and major biopharmaceutical companies such as Johnson & Johnson, Novartis, AstraZeneca, Pfizer, Merck, Sanofi, and GlaxoSmithKline.
Furthermore, welldeveloped healthcare infrastructure and growing number of product launches have fueled regional market growth. Since Europe has approved the first biosimilar drug in 2006, the region has pioneered the regulation of biosimilars.
Over the past 10 years, the region has approved the highest number of biosimilars worldwide. Also, Celltrion and Teva Phamaceuticals’s biosimilar Truxima (rituximab-abbs) was approved in 2017 in Europe and was launched in U.S. in 2019.
Reasons to subscribe to Europe biosimilars market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe biosimilars market databook
-
Our clientele includes a mix of biosimilars market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe biosimilars market , including forecasts for subscribers. This continent databook contains high-level insights into Europe biosimilars market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
Europe biosimilars market size, by country, 2016-2027 (US$M)
Europe Biosimilars Market Outlook Share, 2020 & 2027 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
